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ProteasomeHuntington's disease (HD) is a hereditary neurodegenerative disorder caused by a CAG repeat expansion in the
huntingtin (HTT) gene. Brain-type creatine kinase (CKB) is an enzyme involved in energy homeostasis via the
phosphocreatine–creatine kinase system. Although downregulation of CKB was previously reported in brains
of HDmousemodels and patients, such regulation and its functional consequence inHDare not fully understood.
In the present study, we demonstrated that levels of CKB found in both the soma and processes were markedly
reduced in primary neurons and brains of HD mice. We show for the ﬁrst time that mutant HTT (mHTT)
suppressed the activity of the promoter of the CKB gene, which contributes to the lowered CKB expression in
HD. Exogenous expression of wild-type CKB, but not a dominant negative CKB mutant, rescued the ATP deple-
tion, aggregate formation, impaired proteasome activity, and shortened neurites induced by mHTT. These ﬁnd-
ings suggest that negative regulation of CKB bymHTT is a key event in the pathogenesis of HD and contributes to
the neuronal dysfunction associated with HD. In addition, besides dietary supplementation with the CKB sub-
strate, strategies aimed at increasing CKB expression might lead to the development of therapeutic treatments
for HD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Huntington's disease (HD) is an autosomal neurodegenerative dis-
order with clinical features including uncontrollable motor move-
ments, cognitive impairment, psychiatric syndromes, and impaired
energymetabolism [1]. The causativemutation is an abnormal CAG re-
peat expansion in the huntingtin (HTT) gene. The CAG repeat is trans-
lated into a polyglutamine (polyQ) stretch at the N terminus of the
HTT protein. When the number of CAG repeats exceeds 35, the resul-
tant mutant (m)HTT protein forms nuclear and neuropil inclusions,
and preferentially affects the striatum and cortex [2,3].
Impaired energy metabolism during HD progression was previously
reported in both HD patients and mouse models. Speciﬁcally, reduced
glucose metabolism was found in brains of HD patients [4,5]. Dysfunc-
tion of enzymes involved in the tricarboxylic acid (TCA) cycle, energy
sensors (e.g., AMP-activated protein kinase α1), and a mitochondrial
biogenesis co-activator (peroxisome proliferator-activated receptor
(PPAR) gamma coactivator-1 α, PGC-1α) are altered during HD pro-
gression [6–11]. Impaired mitochondrial respiration and ATP produc-
tion were reported in a striatal progenitor cell line (HdhQ111 cells)
derived from an HD knock-in mouse model [12]. Recently, ATPces, Academia Sinica, Nankang,
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hern).
l rights reserved.depletion was also demonstrated in microwave-ﬁxed brain tissues of
R6/2mice [13]. Those studies collectively suggested that energy deﬁcits
play a major role in HD pathogenesis.
Creatine kinases (CKs) are responsible for the regeneration of ATP
and maintenance of energy homeostasis via the phosphocreatine
(PCr)–CK system. There are 4 isoforms of CK (EC 2.7.3.2): 2 cytosolic
forms (brain-type CK and CKB; andmuscle-type CK and CKM) and 2mi-
tochondrial forms (CKMT1 and CKMT2). These enzymes control ATP
concentrations through the transfer of high-energy phosphate from PCr
to ADP [14,15]. Tissues and cells that consume large amounts of energy
(including the brain) express high levels of CKs [15], suggesting a critical
role of CKs in energy homeostasis. Downregulation of CKB was reported
in numerous neurodegenerative disorders includingAlzheimer's disease,
Pick's disease, and diffuse Lewy body disease [16,17]. Oxidation and re-
duced activity of CKB were previously shown in brains of patients and
mice with HD [18,19]. Levels of CKB protein in the brain and blood of
HDpatients andmicewere respectively lower than those of non-HD sub-
jects and littermate controls [20]. Increased PCr concentrations, resulting
from a reduction in CKB, were also reported in brains of 3 different
mouse models of HD [21]. In addition to what was found in the central
nervous system, we recently reported that CKB was downregulated in
the cochlea of HD mice and might account for the hearing impairment
found in HD patients and 2 mouse models of HD [22]. Those studies col-
lectively suggested that downregulation of CKB is a key event in the en-
ergy dysregulation of HD. Nonetheless, the mechanism underlying the
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are not fully understood. Consistentwith the concept that impairment of
theCK systemcontributes toHDpathogenesis, a few earlier studies dem-
onstrated that supplementation with creatine somewhat ameliorated
HD symptoms [19,23–29]. In the present study, we report for the ﬁrst
time thatmHTT suppressed the activity of the CKB promoter. In addition,
such reduced expression and the resultant inferior activity of CKB are key
pathogenic events of HD, because elevated expression of a functional
CKB protein, but not a CKB variant lacking CK activity, rescued multiple
impaired energy-dependentmachineries (e.g., the ubiquitin proteasome
system (UPS) and neurite outgrowth) in neurons expressing mHTT.
2. Material and methods
2.1. Reagents
All reagents or chemicals were purchased from Sigma Chemical
(St. Louis, MO, USA) unless speciﬁcally mentioned. Dulbecco's modi-
ﬁed Eagle's medium (DMEM) and fetal bovine serum (FBS) were
purchased from HyClone (Logan, UT, USA).
2.2. Animals
Male R6/2 [B6CBA-Tg (HDexon1) 62Gpb/1J] [30] and littermate con-
trols were originally obtained from Jackson Laboratories (Bar Harbor,
ME, USA) and were mated to female control mice (B6CBAFI/J). In total,
67 R6/2 mice and 31 wild-type (WT) littermate controls were used in
this study. Offspring of R6/2 andWTmicewere identiﬁed bypolymerase
chain reaction (PCR) genotyping of genomic DNA extracted from tail tis-
sues. Primer sequences for R6/2 were 5′-CCGCTCAGGTTCTGCTTTTA-3′
and 5′-GGCTGAGGAAGCTGAGGAG-3′. All diets used in the present
study were purchased from LabDiet® (Richmond, VA, USA). Animals
were housed at the Institute of Biomedical Sciences Animal Care Facility
(Taipei, Taiwan) under a 12-h light/dark cycle. Body weights of mice
were recorded 3 times per week. Animal experiments were performed
under protocols approved by the Academia Sinica Institutional Animal
Care and Utilization Committee, Taiwan.
2.3. Tissue collection and protein isolation
Mice were sacriﬁced by decapitation. Tissues were carefully dis-
sected on an ice-cold plate. Collected tissues were stored at −80 °C
until being used. To prepare total protein extracts, tissues from 3 ani-
malswere pooled and homogenized by 20 strokes in an ice-cold buffer
containing 10 mMHEPES (pH 8), 1 mMDTT, 1 mMNa3VO4, and com-
plete protease inhibitor (Roche Diagnostics, Indianapolis, IN, USA).
Total lysates were centrifuged at 1000 g for 10 min at 4 °C to remove
the nuclear fraction as the pellet. The supernatant was collected and
further centrifuged at 150,000 g for 2 h at 4 °C. The resultant pellet
was collected as the membrane fraction, while the supernatant was
collected as the cytosolic fraction. The protein concentrationwasmea-
sured using the Bio-Rad protein assay reagent (Bio-Rad Life Science,
Hercules, CA, USA).
2.4. Western blot analysis
Equal amounts of protein (30 μg)were prepared in sample treatment
buffer and separated by 10% sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) following the method of Laemmli [31].
After electrophoresis, gelswere transferred to Immobilon polyvinylidene
diﬂuoride membranes (Millipore, Bedford, MA, USA), blocked with 5%
skim milk in TBST (0.2 M Tris-base, 1.37 M NaCl, and 0.05% Tween 20),
and probed with the indicated antibody at 4 °C overnight, followed by
incubation with a peroxidase-conjugated secondary antibody for 1 h at
room temperature. The immunoreactive bands were stained using a
light-emitting non-radioactive method (enhanced chemiluminescence;Millipore, Billerica, MA, USA). Antibodies used for the Western blot
analyses were anti-CKB (dilution 1: 5000; HPA001254, Sigma-Aldrich,
St. Louis, MO, USA), anti-α-tubulin (dilution 1:104; Sigma-Aldrich), and
anti-actin (dilution 1:104; MAB1501, Chemicon International, Temecula,
CA, USA).
2.5. RNA puriﬁcation and real-time quantitative reverse-transcription
(qRT)-PCR
Mice were sacriﬁced by decapitation. Tissues were carefully dissect-
ed on ice and immediately placed in an ice-cold RNAlater solution
(Qiagen, Valencia, CA, USA). Collected tissueswere stored in liquid nitro-
gen until being used. Total RNAwas extracted from the striatum or cells
using the Trizol reagent and treated with RNase-free DNase (RQ1;
Promega, Madison, WI, USA) to remove potential contamination of ge-
nomic DNA following the manufacturer's instructions. Complementary
(c)DNA was synthesized from 2.5 μg of total RNA by reverse transcrip-
tion using random primers (Promega) and Superscript II RT (Life Tech-
nologies, Foster City, CA, USA) following the manufacturer's protocols.
The qPCR was performed using SYBR® Green PCR Master Mix (Life
Technologies) on an ABI PRISM® 7700 Sequence Detection System
(Life Technologies). Sequences of primers are listed below: for Ckb
(NM_021273), 5′-AGTTCCCTGATCTGAGCAGC-3′ and 5′-GAATGGCGTC
GTCCAAAGTAA-3′; and forGapdh (NM_008084; used as an internal con-
trol), 5′-AGTTCCCTGATCTGAGCAGC-3′ and 5′-GAATGGCGTCGTCCAAAG
TAA-3′.
2.6. Immunoﬂuorescence staining and quantiﬁcation
Primary cortical neurons (14 days in vitro (DIV)) and cells were
ﬁxed with 4% paraformaldehyde plus 4% sucrose in phosphate-
buffered saline (PBS, pH 7.4) at room temperature for 30 min, and
permeabilized with 0.1% Triton X-100 for an additional 10 min. Freely
ﬂoating brain sections were prepared as previously described [10]. In
brief, animals were anesthetized (sodium pentobarbital, 100 mg/kg,
ip) and perfused with 4% paraformaldehyde in 0.1 M phosphate buffer
(PB). Brain tissues were postﬁxed for 24 h and transferred to 0.1 M PB
containing 30% sucrose for 1 week. Cells or brain sections (30 μm)
were incubated with the desired primary antibody at 4 °C for 18 h,
followed by incubation with the corresponding secondary antibody
for 2 h at room temperature. CKB antibodies were obtained from
Sigma (dilution 1:250; HPA001254). A monoclonal anti-Tuj1 antibody
was purchased from Millipore (dilution 1/2000; MAB5564; Millipore,
Billerica, MA, USA). Nuclei were stained with Hoechst 33258. The goat
anti-rabbit and anti-mouse immunoglobulin G (IgG) respectively con-
jugatedwith Alexa Fluor 488 and 568-conjugated secondary antibodies
(dilution 1:250) were purchased from Invitrogen (Grand Island, NY,
USA). Images were acquired with a confocal microscope (LSM 700,
Carl Zeiss, Jena, Germany) and analyzed with the aid of Zen 2009 lite
software (Carl Zeiss). For quantitation of CKB intensity in primary corti-
cal neurons, at least 30 cells of each experimental condition from 3 in-
dependent experiments were quantiﬁed. For quantitation of CKB
intensity in mouse brains, 3–8 frames of the indicated brain region
(interaural 5.34 mm/bregma 1.54 mm to interaural 3.7 mm/bregma
−0.1 mm) from 3 animals in each groupwere analyzed by ImageJ soft-
ware (http://rsbweb.nih.gov;ij/).
2.7. DNA constructs
The pcDNA3.1-HTT-(Q)25-hrGFP and pcDNA3.1-HTT-(Q)109-hrGFP
constructs encoding an N-terminal fragment of HTT with the indicated
number of polyQ residues fused to humanized Renilla green ﬂuorescent
protein (hrGFP) were created as described previously [34]. The
pcDNA3.1-HTT-(Q)25 and pcDNA3.1-HTT-(Q)158 constructs encoded
anN-terminal fragment of HTTwith the indicated number of polyQ res-
idues [34]. pcDNA3.1-CKB and pcDNA3.1-CKMT1 were generated by
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CKMT1 into the pcDNA3.1 vector which contains a V5 tag. The con-
structs of dominant negative CKB mutants (CKB-C283S) were generat-
ed from pcDNA3.1-CKB by PCR-based site-directed mutagenesis [35].
The CKB promoter constructs were created by subcloning a fragment
of the mouse CKB gene that contained its promoter region (−680 to
+46 bp, +1 as the transcriptional site) into the pGL3 basic vector
which harbors a luciferase reporter gene (Promega). The resultant
pGL3-0.72-kb CKB promoter construct contains binding sites for AP-2
alpha (AP2α), Sp1, and p53. The control construct, pGL3-0.08 CKB pro-
moter (−37 to +46), contained no functional promoter activity. The
pcDNA3.1 DsRed and pcDNA3.1 Snap25:DsRed constructs were gener-
ated to identify transfected cells as previously described [36]. The
primers used in the preparation of these constructs are listed in Supple-
mental Table S1. All constructs were conﬁrmed by DNA sequencing.
2.8. Cell culture
Primary cortical neurons were prepared as previously described
[32,33]. In brief, cortices was carefully removed from R6/2 and control
mice on embryonic day 18 (E18) and digested with 0.05% trypsin-EDTA
(Invitrogen, Grand Island, NY, USA) at 37 °C for 10 min. Dissociated neu-
rons were suspended in the plating medium (modiﬁed Eagle's medium
(MEM) containing 5% FBS, 5% horse serum, 0.6% glucose, 0.5 mM L-gluta-
mine, 1% penicillin/streptomycin, and 1% insulin–tranferrin–selenium
supplement), and plated onto poly-L-lysine coated coverslips at a density
of 200 cells/mm2. After a 3-h incubation, the plating medium was re-
placed with the culture medium (Neurabasal medium supplemented
with 2% B27 (Invitrogen, San Diego, CA, USA), 12.5 mM glutamate,
0.5 mM L-glutamine, and 1% penicillin/streptomycin), and maintained
in an incubation chamber supplied with 5% CO2–95% air at 37 °C.
Striatal progenitor cell lines (ST14A, STHdhQ7, and STHdhQ109)which
were generous gifts from Dr E. Cattaneo (University of Milano, Milan,
Italy), were cultured in DMEM containing 2 Mm L-glutamine plus 10%
FBS, and were maintained in an incubation chamber supplied with 10%
CO2–90% air at 33 °C as described previously [37]. Neuro-2a cells were
purchased from American Type Culture Collection (ATCC; Manassas,
VA, USA) and cultured in Eagle's minimum essential medium (MEM)
plus 10% FBS, 1 mM sodium pyruvate, and 1% penicillin–streptomycin
(Invitrogen Gibco, Grand Island, NY, USA) at 37 °C with 5% CO2. To pre-
vent cells from exceeding 80% conﬂuence, they were routinely
subcultured using a splitting ratio of 1:10 every 2 days [33].
2.9. Transfection and luciferase activity assay
One day before transfection, cells were plated at the density of
2×105 cells/35-mm dish, and transiently transfected with the desired
DNAs using Lipofectamine 2000 (Invitrogen) following the manufac-
turer's protocol. Luciferase activities were determined using a
TD-20/20 Luminometer (Promega) and normalized to the amount of
proteins in the lysate. Four independent experiments using at least 2
different preparations of plasmids were performed for each condition.
2.10. Filter retardation assay
A ﬁlter retardation assay was performed as described previously
[22,38]. In brief, cells or striatal tissues were homogenized in ice-cold
lysis buffer [5 mM Tris–HCl at pH 8.8, 1 mM EDTA, 100 mM NaCl,
5 mM MgCl2, 0.5% Nonidet P-40, and complete protease inhibitor
(Roche Diagnostics)]. Lysates were passed through a 26G needle 10
times to shear the DNA. Protein concentrations were determined.
Equal amounts of lysates were diluted in PBS containing 1% SDS plus
the complete protease inhibitor mix (1 μg/μl), loaded onto a slot-blot
manifold (Bio-Rad) with a cellulose acetate membrane (0.2 μm pole
size), and extensively washed using PBS containing 2% SDS. Blots were
blocked with 5% skim milk in TBS buffer, and incubated with ananti-HTT antibody (1:500; Chemicon International) at 4 °C overnight,
followed by the corresponding secondary antibody for 1 h at room tem-
perature. Immunoreactive bands were detected by enhanced chemilu-
minescence (Thermo Fisher Scientiﬁc) and recorded using Kodak
XAR-5 ﬁlm (Rochester, NY, USA).2.11. ATP measurements
Cells were transiently transfected with the indicated construct(s)
along with 1/10 of the molar amount of an expression construct
(pcDNA3.1 DsRed) to identify transfected cells. To monitor the level of
intracellular ATP, cells were incubated with 5 μM of Magnesium Green
AM (MgGr) ester (an ATP-sensitive dye; Invitrogen Molecular Probes,
Grand Island, NY, USA) in culture medium at 37 °C for 30 min. After
washing with Hank's balanced salt solution (HBSS) twice, cells were in-
cubated in culturemedium for 30 min for de-esteriﬁcation. Live cell im-
ages were acquired using an LSM 780 confocal microscope (Carl Zeiss)
at 37 °C (488 nm excitation and 530 nm emission) and analyzed
using ImageJ software. Because ATP has a higher binding afﬁnity toward
Mg2+ than ADP, when ATP is hydrolyzed into ADP, the released free
Mg2+ will enhance the green ﬂuorescence intensity [39,40]. The inten-
sity of the green ﬂuorescence is inversely correlated with the intracellu-
lar ATP level. To determine the intracellular ATP level, we quantiﬁed the
green ﬂuorescence intensity in DsRed-positive (transfected) cells in
each group, and normalized the value to that of the control group
(pcDNA3.1-(Q)25-HTT plus an empty vector pcDNA3.1). At least 50
cells from 4 independent experiments were quantiﬁed for each experi-
mental condition.2.12. Neurite outgrowth
The neurite outgrowth experiment was modiﬁed from that de-
scribed elsewhere [33]. In brief, Neuro-2a cells were seeded at a density
of 2×105 per 35-mm plate. Cells were transfected with the indicated
construct(s), incubated at 37 °C for 24 h, and transferred to a new
35-mm plate for an additional 4 h to achieve proper attachment. To in-
duce differentiation, cells were exposed to a differentiation mix (MEM
supplemented with 1% FBS and 10 μM of retinoic acid; RA) for 48 h.
Cells were then ﬁxed with 4% paraformaldehyde plus 4% sucrose in
PBS at room temperature for 30 min. Cells containing neurites longer
than 2 cell-body diameters were scored as neurite-positive cells, and
are presented as the percentage of neurite-positive cells of the control
group which was transfected with pcDNA3.1-HTT-(Q)25-hrGFP plus
an empty vector. For each condition, 100–300 transfected cells were
quantiﬁed.2.13. Proteasome activity assay
To determine synaptic proteasome activity, we utilized a proteasome
reporter (Snap25:ZsProSensor-1) which comprises a synaptic protein
(SNAP25) fused to a proteasome-sensitive ﬂuorescent reporter
(ZsProSensor-1) [36]. The level of Snap25:ZsProSensor-1 can be ob-
served as a green ﬂuorescent signal, and inversely reﬂects proteasome
activity. A control reporter (Snap25:DsRed) was used to identify
transfected cells and served as a control protein to normalize the trans-
fection efﬁciency [36]. Cellswere transfectedwith the indicatedHTT con-
struct [pcDNA3.1-(Q)25-HTT, 25Q; or pcDNA3.1-(Q)158-HTT, 158Q]
which encodes exon 1 of HTT containing the indicated number of gluta-
mines (Q), along with an empty vector or the indicated CKB construct,
plus SNAP25:ZsProSensor-1 and SNAP25:DsRed. The green ﬂuorescence
intensitywas quantiﬁed andnormalizedwith theDsRed ﬂuorescence in-
tensity using imageJ software. All datawere normalizedwith the value of
the control group (pcDNA3.1-(Q)25-HTT plus an empty vector).
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Twelve WT and 24 R6/2 mice from the same ﬁlial generation were
supplied with standard diets or diets supplemented with 2% creatine
(LabDiet®, Richmond, VA, USA) from the age of 4 weeks.
2.15. Statistical analysis
All statistical analyses were carried out with Student's t-test unless
indicated otherwise. MgGr ATP assay and proteasome activity were
analyzed using a one-way analysis of variance (ANOVA) followed by
Tukey's multiple-comparison test. Results of the Western blot analy-
ses, RT-qPCR, and immunostaining were analyzed using a two-tailed
Student's t-test. All tests were performed using SigmaStat (vers. 3.1,
Systat Software, Richmond, CA, USA). Signiﬁcance was set at p≤0.05.
All data are shown as the mean±standard error of the mean (SEM).
3. Results
3.1. CKB was downregulated in the striatum of HD mice during disease
progression
We previously showed that CKB was downregulated in cochlea of
HD mice [22]. To assess whether downregulation of CKB also occurred
in the brains of HD mice during HD progression, we evaluated protein
and transcript levels of CKB in the striatum of WT and R6/2 mice at
the age of 7 weeks, when no motor impairment was yet apparent,
and at the age of 12 weeks when R6/2 mice were in the late stage of
HD. A moderate but statistically signiﬁcant downregulation of CKB pro-
tein was observed in R6/2 mice at 7 weeks, while a much more signiﬁ-
cant reduction in CKB protein was found in R6/2 mice at 12 weeks
(Fig. 1A). Interestingly, no change in the level of CKB transcript was
found in 7-week-old R6/2 mice, while a marked decrease of the CKB
transcript was detected in R6/2 mice in the last stage of the disease
(12 weeks old; Fig. 1B). These data suggest that suppression of CKB by
mHTTmight occur at the transcriptional and posttranscriptional levels.Fig. 1. Brain-type creatine kinase (CKB) was downregulated in R6/2 mice during Huntington
indicated mice (n=3 per group) were analyzed by Western blotting using an anti-CKB antib
that of actin, and is presented in the lower panel. (B) Levels of the CKB transcript in the str
indicated animals (n=3 per group), reverse-transcribed into cDNA, and analyzed using a re
normalized to those of GAPDH as a reference gene. Data are presented as the mean±SEM.3.2. mHTT suppressed the activity of the promoter of the CKB gene
We next employed 3 striatal progenitor cell lines (STHdhQ7,
STHdhQ109, and ST14A) to determine the transcriptional regulation of
CKB bymHTT. ST14A cells were derived from rat striatal primordial pri-
mary neurons by immortalization using a temperature-sensitivemutant
of the SV40 large T antigen [41]. Using the same approach, STHdhQ7 and
STHdhQ109 cells were respectively generated from WT mice, the HTT
gene of which contains 7 CAG repeats, and from homozygous knock-in
mice, the HTT gene of which contains 109 CAG repeats [42]. As shown
in Fig. 2A, the endogenous protein level of CKB in STHdhQ109 cells was
markedly lower than that of STHdhQ7 cells. Similarly, transient expres-
sion of mHTT (pcDNA3.1-HTT-(Q)109-hrGFP, 109Q) was sufﬁcient to re-
duce the level of the CKB protein (Fig. 2B). Most importantly, the
transcript level of CKB was dramatically decreased in STHdhQ109 cells
by approximately 80% compared to that of STHdhQ7 cells (Fig. 2C),
suggesting that mHTT might directly suppress the gene expression of
CKB. To investigate the effect of mHTT on the CKB gene promoter, we
subcloned a DNA fragment containing the promoter region of the CKB
gene into the pGL3 construct (pGL3-0.72 CKB). Besides the TATA box,
this CKB promoter fragment also contains binding sites for AP2α, Sp1
and p53 [43–45]. The control promoter construct (pGL3-0.08 CKB)
contained only the TATA box but no other cis-element, and thus had
very low promoter activity. The indicated promoter was transfected
into ST14A cells for promoter analyses. Compared to cells expressing a
control construct (pcDNA3.1-HTT-(Q)25-hrGFP, 25Q), expression of
mHTT (109Q) signiﬁcantly inhibited CKB promoter activity (Fig. 2D).3.3. Subcellular localization of CKB in neurons
To assess the pathological consequence of the downregulation of
CKB in HD, we ﬁrst assessed the cellular localization of CKB in primary
neurons and brains using immunoﬂuorescence staining. As shown in
Fig. 3A, CKB existed in soma and neuronal processes of primary corti-
cal neurons (14 DIV). Although subcellular distributions of CKB in pri-
mary cortical neurons harvested fromWT and R6/2mice were similar,'s disease progression. (A) Cytosolic proteins (30 μg) collected from the striatum of the
ody. Actin was used as the loading control. The level of CKB protein was normalized to
iatum of wild-type (WT) and R6/2 mice. RNAs were collected from the striatum of the
al-time qRT-PCR analysis to determine CKB transcript levels. CKB transcript levels were
* pb0.05, ** pb0.01, *** pb0.001, by Student's t-test.
Fig. 2. Mutant huntingtin (mHTT) suppressed the expression of brain-type creatine kinase (CKB) at the transcriptional level. Cytosolic proteins (30 μg) of STHdhQ7, STHdhQ109, (A) and ST14A
cells overexpressing pcDNA3.1-(Q)25-HTTEX1-hrGFP (25Q) or pcDNA3.1-(Q)109-HTTEX1-hrGFP (109Q; B) were subjected to Western blot analyses. α-Tubulin (A) or actin (B) was used as the
loading control. CKB protein levels were normalized to that of the loading control, and are presented in the lower panel. (C) CKB transcript levels in STHdhQ7 and STHdhQ109 cells were deter-
mined using a real-time qRT-PCR analysis. GAPDHwas used as the reference gene. (D) The 25Q or 109QmHTT construct was co-transfectedwith the indicated promoter construct (pGL3-0.72
CKB or pGL3-0.08 CKB) into ST14A cells for 48 h. Luciferase activity was measured and normalized to the protein content. Values are presented as percentages of the promoter activity of
pGL3-0.72 CKB in the presence of 25Q. Data are presented as the mean±SEM. * pb0.05, ** pb0.01, *** pb0.001, by Student's t-test.
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neurons. We next examined the expression level of CKB protein in
brains of WT and HD mice using immunocytochemical staining
(Fig. 3B, C). Consistent with the above ﬁndings in primary neurons
(Fig. 3A, D) and a previous report [20], digitalized photomicrographs
of brain sections stained with an anti-CKB antibody revealed that
levels of CKB protein in the striatum and cortex of R6/2 mice were
also markedly reduced compared to those of WT mice (Fig. 3B, C, E,
and F). Given the importance of CKB in controlling energy homeosta-
sis, it is likely that multiple energy-demanding machineries in the
soma and neuronal processes might be affected in HD neurons.3.4. Overexpression of CKB attenuated ATP depletion in mHTT-expressing
Neuro-2a cells
To demonstrate the importance of CKB in energy homeostasis, we
performed experiments to determine the effect of CKB on intracellular
ATP levels in a neuronal cell line (Neuro-2a). This cell line was chosen
because it can be induced to differentiate using RA [46]. The intracellu-
lar ATP level was monitored using MgGr AM, an ATP-sensitive dye. The
ﬂuorescence intensity of MgGr is inversely correlated with the intracel-
lular ATP level [39,40]. As shown in Fig. 4A, exogenous expression of
mHTT enhanced the MgGr intensity, suggesting a lower level of ATP
compared to that expressing 25Q. This ﬁnding is consistent with a re-
cent study showing that ATP depletion can be detected in the striatumand frontal cortex of R6/2 mice starting at the age of 8 weeks, before
the onset of motor deﬁcits [13]. Importantly, co-expression of CKB in
the presence of mHTT reduced the MgGr intensity in differentiated
Neuro-2a cells, indicating that elevated expression of CKB rescued ATP
depletion in mHTT-expressing cells.3.5. Overexpression of CKB ameliorated multiple neuronal abnormalities
caused by mHTT
The ubiquitin proteasome system (UPS), which requires ATP, was
reported to play a critical role in the degradation of abnormal and
misfolded proteins [47,48]. Because the CK system plays a critical role
in energy homeostasis and ATP distribution [22,49] and the UPS in syn-
apses of HDneurons is impaired [50], we next examinedwhether lower
CKB levels caused by mHTT led to altered activity of proteasomes in
neuronal processes. Tomonitor synaptic proteasome activity,we gener-
ated a proteasome reporter (Snap25:ZsProSensor-1)which comprises a
synaptic protein (SNAP25) fused to a proteasome-sensitive ﬂuorescent
reporter (ZsProSensor-1) [51–53]. The level of Snap25:ZsProSensor-1
can be observed as a green ﬂuorescent signal, and inversely reﬂects
proteasome activity. A control reporter (Snap25:DsRed) was also creat-
ed to identify transfected cells and normalize the transfection efﬁciency.
Neuro-2a cells were transfected with the indicated HTT construct
[pcDNA3.1-(Q)25-HTT, 25Q; or pcDNA3.1-(Q)158-HTT, 158Q] which
encodes exon 1 of HTT containing the indicated number of glutamines
Fig. 3. Distribution and expression of the brain-type creatine kinase (CKB) protein. (A) Primary cortical neurons were immunostained for CKB (green) and Tuj1 (a neuronalmarker, red).
Nucleiwere stainedwithHoechst 33258 (blue) at 14 days in vitro (DIV). Representative images showCKB expression in soma (left panels) and neurites (right panels) from representative
neurons isolated fromWT and R6/2mice. (B, C) Cortices (B) and striatums (C) of 12-week-oldmaleWT and R6/2mice (n=3)were immunostained for CKB (green) and Tuj1 (a neuronal
marker, red). Nuclei were stained using Hoechst 33258 (blue). Scale bars, 20 μm in A and C; 50 μm in B. CKB intensities in primary cortical neurons (D) and brains (E, the cortex; F, the
striatum) of WT and R6/2 mice were quantiﬁed and are presented as the mean±SEM. * pb0.05, *** pb0.001 by Student's t-test.
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SNAP25:ZsProSensor-1 and SNAP25:DsRed. As shown in Fig. 5A,
Neuro-2a cells expressing 158Q-HTT had a much-stronger green ﬂuo-
rescent signal, reﬂecting lower proteasome activity, than did cells ex-
pressing 25Q-HTT. Most importantly, exogenous expression of WT
CKB signiﬁcantly enhanced proteasome activity (Fig. 5A, B). To deter-
mine whether the kinase activity of CKB was required for the effect of
CKB on proteasome activity, we generated a CKB mutant (CKB-C283S;
[35]) with no CKB activity (Supplementary Fig. S1). UnlikeWT CKB, ex-
pression of CKB-C283S did not enhance proteasome activity (Fig. 5A–B).
Consistent with the observation that CKB enhanced proteasomeactivity, aggregate formation of mHTT was lower in the presence of
WT-CKB, but not C283S-CKB (Fig. 5C). CK activity therefore is critical
for the beneﬁcial effects of CKB of enhancing proteasome activity and
reducing aggregate formation.
The distribution of CKB (Fig. 3A) suggested that CKBmight be an im-
portant energy source throughout the neuronal process. In Neuro-2a
cells, mHTT was shown to inhibit neurite outgrowth [54]. To examine
whether the expression of CKB rescued the inhibition of neurite out-
growth bymHTT, Neuro-2a cells were ﬁrst transfectedwith the expres-
sion construct of mHTT (109Q) along with the indicated CKB variant,
and then were treated with RA (10 μM) for 48 h to induce neurite
Fig. 4. Overexpression of brain-type creatine kinase (CKB) rescued ATP depletion in mutant huntingtin (mHTT)-expressing Neuro-2a cells. (A) Neuro-2a cells were transfected with an
empty vector (V) or a CKB construct, pcDNA3.1-(Q)25-HTTEx1 (25Q) or pcDNA3.1-(Q)158-HTTEx1 (158Q), plus pcDNA3-DsRed at a 4.5: 4.5: 1 ratio as indicated. Cells were treated with
retinoic acid (10 μM) for 72 h to induce differentiation, and incubated with Magnesium Green AM (MgGr) for 30 min. Transfected cells were identiﬁed by the expression of DsRed. The
MgGr intensity was quantiﬁed and normalized to that of the control group (25Q plus an empty vector, V), and is presented in (B). Data are presented as the mean±SEM of 4 independent
experiments. ** pb0.01, by one-way ANOVA. Scale bars, 50 μm.
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neurite outgrowth by Neuro-2a cells (Fig. 6). Most importantly, expres-
sion of WT-CKB, but not C283S-CKB, rescued the inhibition of neurite
outgrowth by mHTT (Fig. 6). Functional CKB therefore is critical for
neuritogenesis.
3.6. Creatine supplementation increased the expression of CKB and re-
duced aggregate formation in the striatum of R6/2 mice
We previously showed that a 2% creatine-supplemented diet in-
creased reduced CKB protein levels in cochlea of R6/2 mice [22]. To
test whether a similar enhancing effect of creatine supplementation
also increased lower CKB levels in the brain, R6/2 mice were treated
with the same creatine supplementation beginning at the age of
4 weeks for 8 weeks. Brain tissues were collected to assess CKB protein
levels. Similar towhatwas found in the cochlea, reduced levels of CKB in
the striatum of R6/2 mice were elevated in creatine-treated R6/2 mice
(Fig. 7A). Consistent with what was observed in Neuro-2a cells, en-
hanced CKB expression by creatine supplementation in R6/2 mouse
brains was associated with lower aggregate formation as assessed by
a ﬁlter retardation assay (Fig. 7B). These ﬁndings support an important
role of CKB in regulating proteasome activity and aggregate formation
during HD progression.
4. Discussion
Results of the present study suggest that mHTTmight suppress the
expression of CKB through at least 2 different mechanisms during HD
progression. Before the onset of motor impairment, a modest but sta-
tistically signiﬁcant downregulation of the CKB protein was evident in
the striatum of R6/2 mice at the age of 7 weeks (Fig. 1). Because no
downregulation of CKB transcripts was found, the lower CKB protein
in R6/2mice at 7 weeks of age likely resulted from posttranscriptional
modiﬁcation. It was interesting to note that CKB is a target of reactive
oxygen species [55,56]. Oxidativemodiﬁcation of CK inhibits the activ-
ity of CK, while also promoting the proteasome-mediated degradation
of CK [57,58]. Since elevated oxidative stresses and oxidative modiﬁ-
cations of CKB were reported in HD [7,19,59], it is very likely that the
enhanced degradation of oxidized CKB proteins occurs at an early
stage of HD and causes the lower CKB protein in the striatum of7-week-old R6/2 mice. Conversely, suppression of the CKB gene
appeared to take place in a late stage of the disease. Using a promoter
assay, we demonstrated that the expression of mHTT inhibited the
promoter activity of CKB (Fig. 2D). Earlier studies showed that mHTT
alters the global transcription proﬁle by interacting with several im-
portant transcription factors [e.g., Sp1 and p53] [60–62]. Note that
the binding site of Sp1 exist in the promoter region of the CKB gene,
and was previously shown to regulate transcription of the CKB gene
[45,63,64]. In addition, p53, which is activated by mHTT [60], is
known to negatively regulate the CKB gene [43]. Abnormal regulation
of these transcription factors by mHTT therefore might mediate the
suppression of CKB in HD. Further characterization of the underlying
mechanism through which mHTT suppresses the CKB gene is critical
because enhanced expression of the CKB gene, as shown in the present
study, provided multiple beneﬁcial effects.
Another important observation shown in the present study is that
the level of CKB in neuronal processes of HD neurons was signiﬁcantly
lower than that of WT neurons (Fig. 3), suggesting a potential energy
deﬁciency in neurons. This is critical for proper neuronal functioning
because the PCr–CK system is known to play a vital role in providing
energy from its production sites to distal energy consumption sites
[65,66]. Interestingly, compensation between multiple energy sources
upon being stressed was reported. For example, intracellular cargo
transport in CKB-null hippocampal neurons appeared normal, except
that the mobility of mitochondria in these cells increased. Therefore,
in the absence of CKB, mitochondria might play a more-important role
inmaintaining normal neuronal functions [67]. Nonetheless, mitochon-
drial transport is also damaged in HD neurons [68–70]. Severe energy
deﬁciencies thus might occur in HD neurons and at least partially
account for the progressive neuropathologies (such as impaired vesicle
transport, organelle transport, protein trafﬁcking, neurotransmitter
release, proteasome activity, and neuritogenesis) of HD neurons
[50,71–75].We showed in the present study that the exogenous expres-
sion of CKB successfully attenuated mHTT-induced energy impairment
(Fig. 4). This ﬁnding not only strengthens the importance of CKB in the
pathogenesis of HD, but also suggests that CKB plays a critical role in
maintaining energy homeostasis in neurons.
We were interested in impacts of the impaired PCr-CK system on
proteasome activities because ATP is required for proteasome func-
tioning [76,77]. The local ATP concentration and energy supply are
Fig. 5. Overexpression of the brain-type creatine kinase (CKB) rescued the proteasome activity impaired by mutant huntingtin (mHTT). (A) Neuro-2a cells were transfected with an empty
vector (V) or the indicated construct of the CKB variant, pcDNA3.1-(Q)25-HTTEx1 (25Q) or pcDNA3.1-(Q)158-HTTEx1 (158Q), plus SNAP25:ZsProSensor-1 and SNAP25:DsRed at a 4:4:1:1 ratio
as indicated. Cells were treated with retinoic acid (10 μM) for 72 h to induce differentiation. (B) Proteasome activity was evaluated by determining the accumulated ZSGreen ﬂuorescence
(green) using confocal microscopy, which was normalized to that of DsRed ﬂuorescence (red). Data were normalized to those of the 25Q plus vector (V)-transfected group, and are presented
as the mean±SEM from 3 independent experiments. * pb0.05, *** pb0.001, by one-way ANOVA. Scale bars, 20 μm. (C) Neuro-2a cells were transfected with pcDNA3.1-(Q)25-HTTEX1-hrGFP
(25Q) or pcDNA3.1-(Q)109-HTTEX1-hrGFP (109Q), along with the indicated CKB variant for 48 h, and subjected to a ﬁlter retardation assay (30 μg/well). Insoluble HTT aggregates retained
on the ﬁlter were detected using an anti-HTT antibody. Actin was the loading control. Quantitative data are shown in the right panel. Data are presented as the mean±SEM. * pb0.05, by
Student's t-test.
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the activity of proteasomes is important for neuronal plasticity
[78,79]. Suppression of proteasome activity was found to arrest
neurite outgrowth and cause “die-back” degeneration in primary neu-
rons [80]. Consistent with lower CKB levels in HD neurons comparedto WT neurons (Fig. 3), neuronal cells expressing mHTT had much
lower proteasome activities in their soma and processes than did con-
trol cells (Fig. 5). Most importantly, we show in the present study that
exogenous expression of a functional CKB (but not the inactive
CKB-C283S) rescued the reduced UPS activity and impaired neurite
Fig. 6. Digitalized photomicrographs of cultured Neuo-2a cells revealed that overexpression of brain-type creatine kinase (CKB) rescued the mutant huntingtin (mHTT)-induced impair-
ment of neurite outgrowth. (A) Neuro-2a cells were transfected with pcDNA3.1-(Q)25-HTTEX1-hrGFP (25Q) or pcDNA3.1-(Q)109-HTTEX1-hrGFP (109Q), along with the indicated CKB var-
iant, and treated with retinoic acid (RA, 10 μM) for 48 h to induce differentiation. Transfected cells were marked as humanized Renilla green ﬂuorescent protein (hrGFP)-expressing cells.
(B) Percentages of transfected, neurite-bearing cellswere quantiﬁed andnormalized to that of cells transfectedwith 25Q. Data arepresented as themean±SEMof 3 experiments. **pb0.01,
*** pb0.001, by Student's t-test. Scale bars, 20 μm.
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tional PCr-CK system is critical for neuronal functioning and plasticity.
Downregulation of CKB might also cause dysfunction of a few
energy-demanding proteins which interact with CKB [81–84]. ForFig. 7. Creatine supplementation increased brain-type creatine kinase (CKB) expression and r
creatine-supplemented diet from the age of 4 weeks for 8 weeks. (A) Striatal tissues were colle
(30 μg per lane). The level of CKB protein was normalized to that of the loading control (α-tub
(mHTT) in the striatum of the indicatedmice was detected using a ﬁlter retardation assay (30 μ
antibody. Tubulin was the loading control. Data are presented as the mean±SEM. * pb0.05, **example, the neuron-speciﬁc K-Cl cotransporter (KCC2) was reported
to interact with CKB [82,84]. KCCs are the major exit route of K+ and
Cl− from mammalian cells, and determine the response of neurons to
γ-aminobutyric acid (GABA) [85]. In the brain, KCC2 is highly expressededuced aggregate formation in the striatum of R6/2 mice. Mice were fed a control or 2%
cted at the age of 12 weeks to assess the level of CKB protein usingWestern blot analyses
ulin), and is presented in the lower panel. (B) Aggregate formation of mutant huntingtin
g/well). Insoluble mHTT aggregates retained on the ﬁlter were detected using an anti-HTT
pb0.01, *** pb0.001 by one-way ANOVA.
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Suppression of CKB by either inhibition of CK activity or expression of a
CKB dominant negativemutant led to the inhibition of KCC2 [83]. Given
the downregulation of CKB in somas and processes of HD neurons, it
would be of great interest to evaluate whether the function of KCC2 is
altered during HD progression.
It is important to note that dietary supplementation with the sub-
strate of CKB (i.e., creatine) not only improved motor dysfunction and
hearing impairment of R6/2 mice [22,28], but also increased CKB ex-
pression in the cochlea and striatum [22] (Fig. 7). Interestingly, the abil-
ity of creatine supplementation to rescue CKB levels in the striatum of
HD mice was moderate (Fig. 7), while downregulated CKB levels in
the cochlea of HD mice were almost completely rescued by creatine
supplementation [22]. Suchmodest effects of creatine supplementation
in the striatum might be due to the limiting ability of creatine to pass
through the blood–brain barrier [88]. The mechanism underlying this
rescue effect of creatine supplementation on CKB expression is current-
ly unknown. One attractive possibility is that creatine supplementation
might enhance levels of the CKB protein due to its antioxidant proper-
ties [89]. Collectively, creatine supplementation enhanced the PCr/CK
system by providing a substrate and enhancing CKB expression, and
subsequently normalized impaired energy metabolism in HD neurons.
5. Conclusions
In conclusion, we demonstrate for the ﬁrst time that mHTT
suppressed promoter activity of the CKB gene, and thus caused
downregulation of CKB. Enhancement of the CKB protein by the exog-
enous expression or dietary creatine supplementation provided ben-
eﬁcial effects to neuronal cells expressing mHTT. Our ﬁndings suggest
that CKB is a potential therapeutic target of HD. Strategies to increase
activities and/or expression levels of CKB might lead to the develop-
ment of novel treatments for HD.
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